ONE-WAYOngoing theme · still written in the latest filings
Uncertainty over regulatory compliance, approvals and launch delays for pharmaceuticals and regenerative medicine products
Risk that changes to pharmaceutical regulations in individual countries, additional requirements from regulatory authorities, and the lack of transparency surrounding approval procedures may delay the start of clinical trials, product launches or business plans. This also includes uncertainty over reimbursement coverage and drug pricing decisions.
Companies37How many companies write about this.
Threads40One company can carry more than one thread here.
PeriodFY2016 →Still being written about.
Directionhurts0 helps · 40 hurts · 0 flat